Article
Gastroenterology & Hepatology
Diego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollon, Jose Miguel Arbones-Mainar, Berta Caballol, Javier P. Gisbert, Montserrat Rivero, Eugenia Sanchez-Rodriguez, Lara Arias Garcia, Ana Gutierrez Casbas, Olga Merino, Lucia Marquez, Viviana Laredo, Maria Dolores Martin-Arranz, Pilar Lopez Serrano, Sabino Riestra Menendez, Carlos Gonzalez-Munoza, Luisa de Castro Parga, Marta Calvo Moya, Esteban Fuentes-Valenzuela, Maria Esteve, Marisa Iborra, Miguel Dura Gil, Manuel Barreiro-De Acosta, Rufo Humberto Lorente-Poyatos, Noemi Mancenido, Margalida Calafat, Iago Rodriguez-Lago, Jordi Guardiola Capo, Maria Antonia Payeras, Victor Jair Morales Alvarado, Carlos Tardillo, Luis Bujanda, Jose Fernando Munoz-Nunez, Yolanda Ber Nieto, Fernando Bermejo, Pedro Almela, Merce Navarro-Llavat, Pilar Martinez Montiel, Cristina Rodriguez Gutierrez, Manuel Van Domselaar, Eva Sese, Teresa Martinez Perez, Elena Ricart, Maria Chaparro, Maria Jose Garcia, Antonio Lopez-Sanroman, Beatriz Sicilia, Beatriz Orts, Alicia Lopez-Garcia, Eduardo Martin-Larraz, Jose Lazaro Perez-Calle, Ruth de Francisco, Esther Garcia-Planella, Eugeni Domenech, Santiago Garcia-Loper
Summary: Ustekinumab shows similar effectiveness in elderly patients with CD as it does in non-elderly patients. The safety profile is also similar, except for a higher rate of de novo neoplasms in elderly patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Maria Chaparro, Ana Garre, Marisa Iborra, Monica Sierra-Ausin, Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Luisa de Castro, Maia Bosca-Watts, Maria Jose Casanova, Alicia Lopez-Garcia, Rufo Lorente, Cristina Rodriguez, Ana Y. Carbajo, Maria Teresa Arroyo, Ana Gutierrez, Joaquin Hinojosa, Teresa Martinez-Perez, Albert Villoria, Fernando Bermejo, David Busquets, Blau Camps, Fiorella Canete, Noemi Mancenido, David Monfort, Merce Navarro-Llavat, Jose Lazaro Perez-Calle, Laura Ramos, Montserrat Rivero, Teresa Angueira, Patricia Camo Monterde, Daniel Carpio, Irene Garcia-de-la-Filia, Carlos Gonzalez-Munoza, Luis Hernandez, Jose M. Huguet, Victor J. Morales, Beatriz Sicilia, Pablo Vega, Isabel Vera, Yamile Zabana, Pilar Nos, Patricia Suarez Alvarez, Cristina Calvino-Suarez, Elena Ricart, Vicent Hernandez, Miguel Minguez, Lucia Marquez, Daniel Hervias Cruz, Saioa Rubio Iturria, Jesus Barrio, Carla Gargallo-Puyuelo, Ruben Frances, Esther Hinojosa, Maria del Moral, Xavier Calvet, Alicia Algaba, Xavier Aldeguer, Jordi Guardiola, Miriam Manosa, Ramon Pajares, Marta Piqueras, Orlando Garcia-Bosch, Pilar Lopez Serrano, Beatriz Castro, Alfredo J. Lucendo, Miguel Montoro, Elena Castro Ortiz, Francisco Mesonero, Esther Garcia-Planella, David A. Fuentes, Inmaculada Bort, Pedro Delgado-Guillena, Lara Arias, Agueda Iglesias, Marta Calvo, Maria Esteve, Eugeni Domenech, Javier P. Gisbert
Summary: Ustekinumab has shown durability and effectiveness in the treatment of ulcerative colitis, even in real life situations. Higher levels of serum C-reactive protein were associated with a lower probability of achieving remission. In the short term, 53% of patients showed a positive response to the treatment.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Maria Chaparro, Iria Baston-Rey, Estela Fernandez-Salgado, Javier Gonzalez Garcia, Laura Ramos, Maria Teresa Diz-Lois Palomares, Federico Arguelles-Arias, Eva Iglesias Flores, Mercedes Cabello, Saioa Rubio Iturria, Andrea Nunez Ortiz, Mara Charro, Daniel Ginard, Carmen Duenas Sadornil, Olga Merino Ochoa, David Busquets, Eduardo Iyo, Ana Gutierrez Casbas, Patricia Ramirez de la Piscina, Marta Maia Bosca-Watts, Maite Arroyo, Maria Jose Garcia, Esther Hinojosa, Jordi Gordillo, Pilar Martinez Montiel, Benito Velayos Jimenez, Cristina Quilez Ivorra, Juan Maria Vazquez Moron, Jose Maria Huguet, Yago Gonzalez-Lama, Ana Isabel Munagorri Santos, Victor Manuel Amo, Maria Dolores Martin-Arranz, Fernando Bermejo, Jesus Martinez Cadilla, Cristina Rubin de Celix, Paola Fradejas Salazar, Antonio Lopez San Roman, Nuria Jimenez, Santiago Garcia Lopez, Anna Figuerola, Itxaso Jimenez, Francisco Jose Martinez Cerezo, Carlos Taxonera, Pilar Varela, Ruth de Francisco, David Monfort, Gema Molina Arriero, Alejandro Hernandez Camba, Francisco Javier Garcia-Alonso, Manuel Van Domselaar, Ramon Pajares Villarroya, Alejandro Nunez, Francisco Rodriguez Moranta, Ignacio Marin-Jimenez, Virginia Robles Alonso, Maria del Mar Martin Rodriguez, Patricia Camo-Monterde, Ivan Garcia Tercero, Mercedes Navarro Llavat, Lara Arias Garcia, Daniel Hervias Cruz, Sara Sulleiro, Cynthia Novella, Eugenia Vispo, Manuel Barreiro-de Acosta, Javier P. Gisbert
Summary: This large retrospective study demonstrates the effectiveness and safety of ustekinumab as a short- and long-term treatment option for patients with Crohn's disease in real-world clinical practice, including those with refractory disease.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Qian Cao, Chunxiao Chen, Xiang Gao, Yan Chen, Naizhong Hu, Jie Liang, Kaichun Wu
Summary: Research shows that ustekinumab is more effective in treating Crohn's disease than anti-tumor necrosis factor treatment for patients who did not respond to previous treatment. The remission rates of ustekinumab are superior to those in the UNITI-1 study.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Miriam Manosa, Agnes Fernandez-Clotet, Pilar Nos, Maria Dolores Martin-Arranz, Noemi Mancenido, Ana Carbajo, Esther Hinojosa, Alejandro Hernandez-Camba, Roser Munoz-Perez, Maia Bosca-Watts, Marta Calvo, Monica Sierra-Ausin, Eugenia Sanchez-Rodriguez, Manuel Barreiro-de Acosta, Alejandro Nunez-Alonso, Yamile Zabana, Lucia Marquez, Javier P. Gisbert, Jordi Guardiola, Empar Sainz, Pedro Delgado-Guillena, David Busquets, Manuel van Domselaar, Eva Girona, Rufo Lorentea, Diego Casas-Deza, Jose M. Huguet, Sergio Maestro, M. Jose Cabello, Jesus Castro, Marisa Iborra, Fiorella Canete, Margalida Calafat, Eugeni Domenech
Summary: This study found that ustekinumab and vedolizumab are effective in preventing postoperative recurrence in high-risk Crohn's disease patients. However, further controlled trials comparing these drugs with conventional therapies are needed.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Amanda M. Johnson, Maria Barsky, Waseem Ahmed, Samantha Zullow, Jonathan Galati, Vipul Jairath, Neeraj Narula, Farhad Peerani, Benjamin H. Click, Elliot S. Coburn, ThucNhi Tran Dang, Stephanie Gold, Manasi Agrawal, Rajat Garg, Manik Aggarwal, Danah Mohammad, Brendan Halloran, Gursimran S. Kochhar, Hannah Todorowski, Nabeeha Mohy Ud Din, James Izanec, Amanda Teeple, Chris Gasink, Erik Muser, Zhijie Ding, Arun Swaminath, Komal Lakhani, Dan Hogan, Samit Datta, Ryan C. Ungaro, Brigid S. Boland, Matthew Bohm, Monika Fischer, Sashidhar Sagi, Anita Afzali, Thomas Ullman, Garrett Lawlor, Daniel C. Baumgart, Shannon Chang, David Hudesman, Dana Lukin, Ellen J. Scherl, Jean-Frederic Colombel, Bruce E. Sands, Corey A. Siegel, Miguel Regueiro, William J. Sandborn, David Bruining, Sunanda Kane, Edward V. Loftus, Parambir S. Dulai
Summary: This study evaluated the real-world effectiveness and safety of ustekinumab in patients with Crohn's disease. The results demonstrated that ustekinumab is a safe and effective treatment option for Crohn's disease, especially for biologic-naive patients.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Anders Forss, Mark Clements, Par Myrelid, Hans Strid, Charlotte Soderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olen, Jonas Halfvarson, Jonas F. Ludvigsson
Summary: This study demonstrates the long-term clinical effectiveness of ustekinumab in patients with active Crohn's disease, as well as its improvement in Health-related Quality of Life (HRQoL) measures.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Nikolas Plevris, James Fulforth, Spyros Siakavellas, Andrew Robertson, Rebecca Hall, Amy Tyler, Philip W. Jenkinson, Iona Campbell, Cher Shiong Chuah, Claire Kane, Jennifer Veryan, Wai Liam Lam, Jayne Saunders, Christopher Kelly, Daniel Gaya, Hasnain Jafferbhoy, Jonathan C. Macdonald, John Paul Seenan, Craig Mowat, Graham Naismith, Lindsay F. Potts, Diarmid Ian Sutherland, David Watts, Ian Arnott, Gillian Bain, Gareth Jones, Charlie W. Lees
Summary: The study aimed to evaluate the real-world effectiveness and safety of ustekinumab for treating Crohn's disease in patients in Scotland. Results showed that ustekinumab is a safe and effective treatment for complex Crohn's disease, with good rates of clinical remission, mucosal healing, and deep remission observed in the study.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Maria Chaparro, Ana Garre, Francisco Mesonero, Cristina Rodriguez, Manuel Barreiro-de Acosta, Jesus Martinez-Cadilla, Maria T. Arroyo, Noemi Mancenido, Monica Sierra-Ausin, Isabel Vera-Mendoza, Maria Jose Casanova, Pilar Nos, Carlos Gonzalez-Munoza, Teresa Martinez, Maia Bosca-Watts, Margalida Calafat, David Busquets, Eva Girona, Jordina Llao, Maria Dolores Martin-Arranz, Marta Piqueras, Laura Ramos, Gerard Suris, Fernando Bermejo, Ana Y. Carbajo, Diego Casas-Deza, Agnes Fernandez-Clotet, Maria J. Garcia, Daniel Ginard, Ana Gutierrez-Casbas, Luis Hernandez, Alfredo J. Lucendo, Lucia Marquez, Olga Merino-Ochoa, Francisco J. Rancel, Carlos Taxonera, Antonio Lopez Sanroman, Saioa Rubio, Eugeni Domenech, Javier P. Gisbert
Summary: The study findings indicate that tofacitinib is effective and safe in treating active ulcerative colitis. However, a significant proportion of patients discontinue the drug over time, mainly due to primary failure.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
A. Hernandez-Camba, L. Arranz, I Vera, D. Carpio, M. Calafat, A. J. Lucendo, C. Taxonera, S. Marin, M. J. Garcia, G. Suris Marin, E. Sanchez Rodriguez, A. Y. Carbajo, M. L. De Castro, M. Iborra, A. Martin-Cardona, I Rodriguez-Lago, D. Busquets, F. Bertoletti, M. Sierra Ausin, C. Tardillo, J. Huguet Malaves, L. Bujanda, A. Castano, E. Domenech, L. Ramos
Summary: This study evaluated the use of MMF in IBD and found that it has some effectiveness and good safety in treating IBD patients.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Gastroenterology & Hepatology
Rajat Garg, Manik Aggarwal, Robert Butler, Jean Paul Achkar, Bret Lashner, Jessica Philpott, Benjamin Cohen, Taha Qazi, Florian Rieder, Miguel Regueiro, Benjamin Click
Summary: UST is safe and effective in elderly CD patients, with similar outcomes as nonelderly patients. Age is not associated with clinical outcomes, while differences exist between elderly and nonelderly patients in Crohn's disease activity and prior biologic use. Real-world data in this IBD population can help inform biologic positioning.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Francisco Mesonero, Jesus Castro-Poceiro, Jose M. Benitez, Blau Camps, Marisa Iborra, Alicia Lopez-Garcia, Paola Torres, Maria Esteve, Joan Tosca, Federico Bertoletti, Pedro Almela, Xavier Calvet, Isabel Vera, Luis Bujanda, Fernando Gomollon, Cristina Rodriguez, Beatriz Antolin, David Busquets, Alejandro Hernandez, Montserrat Rivero, David Monfort i Miquel, Andres Castano-Garcia, Javier P. Gisbert, Eugeni Domenech, Antonio Lopez-Sanroman
Summary: Methotrexate monotherapy showed effectiveness in Crohn's disease patients, especially in those who had failed previous anti-TNF alpha treatments. The study suggests that the effectiveness may be associated with short-term treatment response.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Rheumatology
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, Tatiana Korotaeva, Frederic Lavie, Wim Noel, Michael T. Nurmohamed, Petros P. Sfikakis, Mohamed Sharaf, Elke Theander, Josef S. Smolen
Summary: This study evaluated the real-world persistence and effectiveness of the IL-12/23 inhibitor ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years. The results showed that the proportion of patients still on their initial treatments after 3 years was similar with ustekinumab and TNFi, but ustekinumab had a lower rate of adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Gastroenterology & Hepatology
Marisa Iborra, Rocio Ferreiro-Iglesias, Martin-Arranz Maria Dolores, Francisco Mesonero Gismero, Alejandro Minguez, Sol Porto-Silva, Laura Garcia-Ramirez, Irene Garcia de la Filia, Mariam Aguas, Laura Nieto-Garcia, Cristina Suarez Ferrer, Guillermo Bastida, Manuel Barreiro-De-Acosta, Pilar Nos
Summary: This study aimed to assess the effectiveness, safety, and pharmacokinetics of ustekinumab in a large cohort of refractory ulcerative colitis (UC) patients. The results demonstrated that ustekinumab showed long-term effectiveness and a favorable safety profile in the real-world setting.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Psychiatry
Jonne Lintunen, Heidi Taipale, Antti Tanskanen, Ellenor Mittendorfer-Rutz, Jari Tiihonen, Markku Lahteenvuo
Summary: In the treatment of SCHAFF, clozapine, long-acting injectable antipsychotics, and combination therapy with mood stabilizers were associated with the best outcomes, while the use of quetiapine and benzodiazepines were associated with the worst outcomes.
SCHIZOPHRENIA BULLETIN
(2021)
